Elbit Medical Technologies’ two portfolio investments continue to advance. Notably, Gamida Cell announced a $53m IPO on Nasdaq in late October and presented NiCord data at the American Society of Hematology (ASH) annual meeting in December. InSightec reported record revenues for Q318 and received FDA approval for ExAblate Neuro compatibility with Siemens’ magnetic resonance (MR) scanners.
06 Dec 2018
Elbit Medical Technologies - Another FDA approval and a US IPO
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Elbit Medical Technologies - Another FDA approval and a US IPO
Elbit Medical Technologies Ltd (EMTC.M:TAE) | 0 0 0.0%
- Published:
06 Dec 2018 -
Author:
Maxim Jacobs -
Pages:
6
Elbit Medical Technologies’ two portfolio investments continue to advance. Notably, Gamida Cell announced a $53m IPO on Nasdaq in late October and presented NiCord data at the American Society of Hematology (ASH) annual meeting in December. InSightec reported record revenues for Q318 and received FDA approval for ExAblate Neuro compatibility with Siemens’ magnetic resonance (MR) scanners.